Cellectar Biosciences is seeking FDA approval for its drug candidate CLR 125, which is designed to treat Triple-Negative Breast Cancer (TNBC).
1 report, 0 independent
Updated Jun 24
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cellectar Biosciences is seeking FDA approval for its drug candidate CLR 125, which is designed to treat Triple-Negative Breast Cancer (TNBC).
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cellectar Biosciences (United States)
company in Madison, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- Unknown outlet